We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

138 hedge funds and large institutions have $183M invested in Nektar Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 37 increasing their positions, 34 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

691% more call options, than puts

Call options by funds: $182K | Put options by funds: $23K

29% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 17

9% more capital invested

Capital invested by funds: $168M → $183M (+$15M)

4% more funds holding

Funds holding: 133 → 138 (+5)

9% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 34

0.19% more ownership

Funds ownership: 4.91% → 5.1% (+0.19%)

Holders
138
Holders Change
+5
Holders Change %
+3.76%
% of All Funds
1.98%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
37
Reduced
34
Closed
17
Calls
$182K
Puts
$23K
Net Calls
+$159K
Net Calls Change
+$186K

Top Buyers

1
EAM
Eventide Asset Management
Massachusetts
+$2.38M
2
BCM
Bridgeway Capital Management
Texas
+$1.73M
3
WP
Woodline Partners
California
+$1.41M
4
Northern Trust
Northern Trust
Illinois
+$1.21M
5
BlackRock
BlackRock
New York
+$1.03M

Top Sellers

1
DTC
Deep Track Capital
Connecticut
-$2.48M
2
Morgan Stanley
Morgan Stanley
New York
-$923K
3
GCP
GSA Capital Partners
United Kingdom
-$911K
4
Two Sigma Investments
Two Sigma Investments
New York
-$567K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$426K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$20.8M +$1.03M +54,245 +5%
DTC
2
Deep Track Capital
Connecticut
$20.7M -$2.48M -130,190 -11%
Vanguard Group
3
Vanguard Group
Pennsylvania
$17.1M +$195K +10,220 +1%
EAM
4
Eventide Asset Management
Massachusetts
$12.2M +$2.38M +124,727 +25%
SC
5
Samlyn Capital
New York
$12M -$328K -17,196 -3%
Citadel Advisors
6
Citadel Advisors
Florida
$9.04M – – –
Primecap Management
7
Primecap Management
California
$7.69M -$137K -7,200 -2%
Acadian Asset Management
8
Acadian Asset Management
Massachusetts
$7.35M +$979K +51,352 +16%
Millennium Management
9
Millennium Management
New York
$6.58M +$511K +26,817 +9%
NCM
10
Nantahala Capital Management
Connecticut
$5.34M – – –
TCM
11
TCG Crossover Management
California
$5.2M – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$5.15M -$190K -9,961 -4%
State Street
13
State Street
Massachusetts
$4.35M +$452K +23,717 +12%
Renaissance Technologies
14
Renaissance Technologies
New York
$4.33M +$17.5K +920 +0.4%
Jacobs Levy Equity Management
15
Jacobs Levy Equity Management
New Jersey
$3.63M -$102K -5,332 -3%
MAM
16
Monaco Asset Management
Monaco
$2.6M -$215K -11,281 -8%
Goldman Sachs
17
Goldman Sachs
New York
$2.32M +$20.3K +1,063 +0.9%
WP
18
Woodline Partners
California
$2.25M +$1.41M +73,918 +178%
SC
19
Shay Capital
New York
$2.07M -$311K -16,340 -13%
Two Sigma Advisers
20
Two Sigma Advisers
New York
$1.95M -$426K -22,367 -18%
Charles Schwab
21
Charles Schwab
California
$1.89M -$42.6K -2,237 -2%
Northern Trust
22
Northern Trust
Illinois
$1.82M +$1.21M +63,494 +212%
Two Sigma Investments
23
Two Sigma Investments
New York
$1.77M -$567K -29,734 -25%
BCM
24
Bridgeway Capital Management
Texas
$1.77M +$1.73M +90,807 New
IC
25
Ikarian Capital
Texas
$1.71M – – –
1
2 3 4 5

NKTR Hedge Fund Activity: Q3 2024 in Review

138 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2024, worth a combined $183M — up 8.9% from $168M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new NKTR positions and 17 closed out — a net gain of 5 holders — while 37 added to existing stakes and 34 trimmed.

The largest buyer was Eventide Asset Management, adding an estimated $2.38M. The largest seller was Deep Track Capital, cutting an estimated $2.48M.

  • 138 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2024, up from 133 in Q2 2024.
  • Funds reported $183M of Nektar Therapeutics stock for Q3 2024, up 8.9% quarter-over-quarter.
  • 22 funds opened new Nektar Therapeutics positions in Q3 2024 and 17 closed out, a net change of +5 holders.
  • The largest Nektar Therapeutics buyer in Q3 2024 was Eventide Asset Management, an estimated $2.38M added.
  • The largest Nektar Therapeutics seller in Q3 2024 was Deep Track Capital, an estimated $2.48M sold.

Based on aggregated 13F filings for Q3 2024.